SHORT MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 11:12:03 28/06/2024 pm IST | ||
| 34.37 EUR | +1.81% |
|
| Current month | +8.05% | ||
| 1 month | +7.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 34.37 | +1.81% |
| 27/24/27 | 33.76 | +0.12% |
| 26/24/26 | 33.72 | -0.18% |
| 25/24/25 | 33.78 | +0.09% |
| 24/24/24 | 33.75 | +0.12% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 11:12 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0EMZ |
| ISIN | DE000VU0EMZ2 |
| Date issued | 01/12/2022 |
| Strike | 4,318 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.58 € |
|---|---|
| Lowest since issue | 13.81 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,745
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.20%
- Stock Market
- Certificates
- Certificat
